NPB-01(Intravenous Immunoglobulin) Therapy for Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids.
Phase of Trial: Phase III
Latest Information Update: 01 Aug 2015
Price : $35 *
At a glance
- Drugs Immune globulin (Primary)
- Indications Stevens-Johnson syndrome; Toxic epidermal necrolysis
- Focus Therapeutic Use
- Sponsors Nihon Pharmaceutical
- 01 Jul 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 10 Jun 2014 New trial record